Abstract
Tumor mutations are key in the generation of anticancer immunity. Tumors with high mutational burden (TMB) are more likely to harbor high levels of neoantigens that make them targets of activated immune cells and thus may have superior and/or prolonged response to immune checkpoint inhibitors (ICI) when compared to TMB-low counterparts. A recently published biomarker analysis of KEYNOTE-158 reported that tumors with TMB-high status had a higher objective response to pembrolizumab monotherapy than non-TMB-high tumors leading to FDA approval of Pembrolizumab in TMB-high solid tumors. Importantly, among TMB-high responses, 57% had durable response >12 months. Reported objective response in endometrial cancer cohort was 46.6% in TMB-high (7/15) vs 4.9% (4/67) non-TMB high. In our study, we aimed to further investigate this identified association between TMB-high status and sensitivity to ICI in endometrial cancer by evaluating clinical benefit and duration of clinical benefit in TMB-high vs TMB-low patient groups.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
